self-amplifying mRNA COVID-19 vaccine demonstrates superior immune response compared with mRNA vaccine at 12 months post-vaccination
CSL and Arcturus Therapeutics announce the results of a head-to-head study demonstrating that self-amplifying (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other variants, and at one-sixth the dose of the comparator (5 ug vs 30 ug, respectively)
The data, presented as a poster at the OPTIONS XII for the Control of Influenza conference, highlights 12-month follow-up analysis of the Phase III trial conducted in Japan by Meiji Seika Pharma, evaluating a booster dose of ARCT 154, showing that the vaccine elicited superior immunogenicity and antibody persistence over Comirnaty for up to 12 months postvaccination, against multiple SARS-CoV-2 strains and in both younger and older adult age groups.
The 12-month results from the ARCT 154 study continue to establish the durability of immune response from this self-amplifying mRNA vaccine and reinforce the ability of this vaccine to provide protection against COVID-19 at lower doses compared to conventional mRNA vaccines,” said Jonathan Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL. We are proud to showcase at the 2024 OPTIONS conference with these important data about the first sa-mRNA COVID-19 vaccine now approved in Japan.
Additional data presented by CSL and Arcturus finds that the bivalent formula, ARCT 2301, developed on the same platform as ARCT 154, induces superior immunogenicity over conventional bivalent mRNA vaccine Comirnaty that persists against key variants up to six months postvaccination.
The recent surge in COVID-19 infections and the emerging new variants illustrate the critical need for vaccines that provide a longer duration of protection compared to conventional mRNA vaccines,said Igor Smolenov, M.D., Ph.D. Chief Development Officer of Arcturus Therapeutics. "These compelling new studies reaffirm that these sa-mRNA vaccines have the potential to offer potent protection against COVID-19.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins